Study Evaluating Sirolimus in Kidney Transplant Recipients.
A Randomized, Open Label Study to Evaluate the Effects of a Regimen With Sirolimus,Low Doses Cyclosporine and Steroids vs a Regimen With Sirolimus and Steroids, After an Induction Period With Basiliximab, Sirolimus,Cyclosporine and Steroids in de Novo Renal Transplant Patients.
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
A PHASE3 clinical study on Graft vs Host Disease and Kidney Failure, this trial is completed. The trial is conducted by Wyeth is now a wholly owned subsidiary of Pfizer and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jan 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Wyeth is now a wholly owned subsidiary of Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bari, Italy , Bologna, Italy , Cagliari, Italy , Florence, Italy , L’Aquila, Italy , Milan, Italy , Palermo, Italy , Pisa, Italy , Rome, Italy , Sassari, Italy and 3 more locations